PTH and hypercalcemia disease: The FDA approval for recombinant salmon calcitonin for treating hypercalcemia and postmenopausal osteoporosis in 2005 [29] and the parathyroid hormone (PTH) for osteoporosis in 2002 [27] are two success stories of the recombinant technology in the production of peptide therapeutics.